| 杨春,杜心芳,夏淑林.拉米夫定治疗代偿期乙型病毒性肝炎肝硬化患者疗效观察[J].浙江中西医结合杂志,2012,22(12):932-934 |
| 拉米夫定治疗代偿期乙型病毒性肝炎肝硬化患者疗效观察 |
| Long-term Efficacy and Safety of Lamivudine for Treatment of Compensated Cirrhosis Due to HepatitisB |
| 投稿时间：2012-06-04 |
| DOI： |
| 中文关键词: 乙型病毒性肝炎
肝硬化
代偿期
拉米夫定
疗效 |
| 英文关键词:hepatitis B
cirrhosis
compensation
lamivudine
efficacy |
| 基金项目:浙江省宁波市医学科技计划项目（No.2010A20） |
|
| 摘要点击次数: 1480 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的：观察拉米夫定治疗代偿期乙型肝炎肝硬化的疗效。方法：20例HBeAg阳性和27例
HBeAg阴性的代偿期乙肝肝硬化患者接受拉米夫定治疗，观察两组治疗12周、24周和240周时的
疗效。结果：在治疗12周时HBeAg阳性组HBV-DNA转阴18例（90.0%）、24周时HBV-DNA转阴
15 例（75.0%）、240 周时转阴 15 例（75.0%），P 分别为 0.478、0.726 和 0.023：而 HBeAg 阴性组
HBV-DNA在12周、24周和240周时分别转阴21例（77.8%）、19例（70.4%）、27例（100.0%）；两组在
12周、24周和240周时ALT复常率均无显著性差异（P=0.886、0.537和0.805）；在27例HBV-DNA定
量>106copies/mL 与 20 例 HBV-DNA 定量<106copies/mL 两组中，治疗 12 周、24 周和 240 周时
HBV-DNA转阴例数分别为19例（70.0%）和20例（100%，P=0.047）、17例（63.0%）和17例（85.0%，
P=0.129）、22例（81.5%）和20例（100.0%，P=0.204）。两组在12周、24周和240周时ALT复常率均
无显著性差异（P=0.314、0.978和1.0）。结论：拉米夫定治疗代偿期乙肝肝硬化有很好的抗病毒活
性。 |
| 英文摘要: |
| Objective: To investigate the efficacy and safety of lamivudine in patients with compensated cirrhosis
due to hepatitis B. Methods: Twenty HBeAg-positive compensated cirrhosis due to hepatitis B patients and 27
HBeAg-negative chronic hepatitis B patients admitted to our hospital from April 2000 to April 2005 received la?
mivudine for 5 years. The efficacy was evaluated at 12, 24, and 240 weeks after initial treatment. Results: In
HBeAg-positive group, levels of HBV-DNA less than 1000 copies/ml were achieved in 18(90.0%, P=0.478),15
(75.0%, P=0.726), and 15(75.0%, P=0.023) patients at 12, 24, and 240 weeks after treatment, respectively; and
in HBeAg-negative group, levels of HBV-DNA less than 1000 copies/ml were achieved in 21(77.8%),19(70.4%),
and 27(100.0%) patients at 12, 24, and 240 weeks after treatment, respectively. Levels of alanine aminotransferase
(ALT) normalized in the 2 groups did not differ at 12, 24, and 240 weeks after treatment(P=0.886, 0.537,
0.805).
In 27 patients with levels of HBV-DNA more than 106 copies/ml and 20 patients with levels of
HBV-DNA less than 106 copies/ml, levels of HBV-DNA less than 100 copies/ml were achieved in 19 and 20
(70.0% vs 100%, P=0.047) patients, 17 and 17 (63.0% vs 85.0%, P=0.129), and 22 and 20 (81.5% vs 100%,
P=0.204) at 12, 24, and 240 weeks after treatment, respectively; and no significant difference in ALT normaliza?
tion rate was noted between the 2 groups(P=0.314,0.978,1.0). Conclusion: Lamivudine has satisfactory long-term
anti-viral effect on compensated cirrhosis from HBV infection. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
